Sarah Hughes to Clinical Trials as Topic
This is a "connection" page, showing publications Sarah Hughes has written about Clinical Trials as Topic.
Connection Strength
1.188
-
Hughes S, Wells K, McSorley P, Freeman A. Preparing individual patient data from clinical trials for sharing: the GlaxoSmithKline approach. Pharm Stat. 2014 May-Jun; 13(3):179-83.
Score: 0.356
-
Hughes S, Harris J, Flack N, Cuffe RL. The statistician's role in the prevention of missing data. Pharm Stat. 2012 Sep-Oct; 11(5):410-6.
Score: 0.317
-
Hughes S, Cuffe RL, Lieftucht A, Garrett Nichols W. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial. Pharm Stat. 2009 Jan-Mar; 8(1):25-37.
Score: 0.248
-
Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat. 2008 Apr-Jun; 7(2):121-9.
Score: 0.235
-
Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, Hughes SH, Yeo JM, Lapierre DH. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009 May 01; 51(1):20-8.
Score: 0.016
-
Carroll K, Ross HC, Evans D, France L, Hemmings R, Hughes S, Lynn F, Mahoney P, Phillips A. Conditional approval: discussion points from the PSI conditional approval expert group. Pharm Stat. 2008 Oct-Dec; 7(4):263-9; discussion 270-1.
Score: 0.015